| Year |
Citation |
Score |
| 2023 |
Herrejon Chavez F, Luo H, Cifani P, Pine A, Chu KL, Joshi S, Barin E, Schurer A, Chan M, Chang K, Han GYQ, Pierson AJ, Xiao M, Yang X, Kuehm LM, ... ... Vu LP, et al. RNA binding protein SYNCRIP maintains proteostasis and self-renewal of hematopoietic stem and progenitor cells. Nature Communications. 14: 2290. PMID 37085479 DOI: 10.1038/s41467-023-38001-x |
0.711 |
|
| 2023 |
Jin Z, MacPherson K, Liu Z, Vu LP. RNA modifications in hematological malignancies. International Journal of Hematology. PMID 36929506 DOI: 10.1007/s12185-023-03576-0 |
0.396 |
|
| 2023 |
Liu Y, Ramkumar N, Vu LP. RNA deadenylation complexes in development and diseases. Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire. 101: 131-147. PMID 36645883 DOI: 10.1139/bcb-2022-0325 |
0.386 |
|
| 2022 |
Ghashghaei M, Le CT, Shaalan H, Escano L, Yue M, Arsalan A, Rouhi A, Nguyen TA, Vu LP. miR-148a-3p and DDX6 functional link promotes survival of myeloid leukemia cells. Blood Advances. PMID 36322827 DOI: 10.1182/bloodadvances.2022008123 |
0.309 |
|
| 2021 |
Prieto C, Nguyen DTT, Liu Z, Wheat J, Perez A, Gourkanti S, Chou T, Barin E, Velleca A, Rohwetter T, Chow A, Taggart J, Savino AM, Hoskova K, Dhodapkar M, ... ... Vu LP, et al. Transcriptional control of CBX5 by the RNA binding proteins RBMX and RBMXL1 maintains chromatin state in myeloid leukemia. Nature Cancer. 2: 741-757. PMID 34458856 DOI: 10.1038/s43018-021-00220-w |
0.675 |
|
| 2020 |
Nguyen DTT, Lu Y, Chu KL, Yang X, Park SM, Choo ZN, Chin CR, Prieto C, Schurer A, Barin E, Savino AM, Gourkanti S, Patel P, Vu LP, Leslie CS, et al. HyperTRIBE uncovers increased MUSASHI-2 RNA binding activity and differential regulation in leukemic stem cells. Nature Communications. 11: 2026. PMID 32332729 DOI: 10.1038/S41467-020-15814-8 |
0.72 |
|
| 2019 |
Cheng Y, Luo H, Izzo F, Pickering BF, Nguyen D, Myers R, Schurer A, Gourkanti S, Brüning JC, Vu LP, Jaffrey SR, Landau DA, Kharas MG. mA RNA Methylation Maintains Hematopoietic Stem Cell Identity and Symmetric Commitment. Cell Reports. 28: 1703-1716.e6. PMID 31412241 DOI: 10.1016/J.Celrep.2019.07.032 |
0.751 |
|
| 2019 |
Vu LP, Cheng Y, Kharas MG. The Biology of mA RNA Methylation in Normal and Malignant Hematopoiesis. Cancer Discovery. 9: 25-33. PMID 30578356 DOI: 10.1158/2159-8290.CD-18-0959 |
0.685 |
|
| 2018 |
Vu LP, Kharas MG. Targeting the Residual Leukemia Cells after Chemotherapy. Cancer Cell. 34: 353-355. PMID 30205040 DOI: 10.1016/j.ccell.2018.08.012 |
0.636 |
|
| 2018 |
Greenblatt SM, Man N, Hamard PJ, Asai T, Karl D, Martinez C, Bilbao D, Stathais V, McGrew-Jermacowicz A, Duffort S, Tadi M, Blumenthal E, Newman S, Vu L, Xu Y, et al. CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis. Cancer Cell. 33: 1111-1127.e5. PMID 29894694 DOI: 10.1016/j.ccell.2018.05.007 |
0.441 |
|
| 2017 |
Vu LP, Pickering BF, Cheng Y, Zaccara S, Nguyen D, Minuesa G, Chou T, Chow A, Saletore Y, MacKay M, Schulman J, Famulare C, Patel M, Klimek VM, Garrett-Bakelman FE, et al. The N(6)-methyladenosine (m(6)A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nature Medicine. PMID 28920958 DOI: 10.1038/Nm.4416 |
0.722 |
|
| 2017 |
Huber FM, Greenblatt SM, Davenport AM, Martinez C, Xu Y, Vu LP, Nimer SD, Hoelz A. Histone-binding of DPF2 mediates its repressive role in myeloid differentiation. Proceedings of the National Academy of Sciences of the United States of America. PMID 28533407 DOI: 10.1073/Pnas.1700328114 |
0.42 |
|
| 2017 |
Vu LP, Prieto C, Amin EM, Chhangawala S, Krivtsov A, Calvo-Vidal MN, Chou T, Chow A, Minuesa G, Park SM, Barlowe TS, Taggart J, Tivnan P, Deering RP, Chu LP, et al. Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nature Genetics. PMID 28436985 DOI: 10.1038/Ng.3854 |
0.719 |
|
| 2016 |
Taggart J, Ho TC, Amin E, Xu H, Barlowe TS, Perez AR, Durham BH, Tivnan P, Okabe R, Chow A, Vu L, Park SM, Prieto C, Famulare C, Patel M, et al. MSI2 is required for maintaining activated myelodysplastic syndrome stem cells. Nature Communications. 7: 10739. PMID 26898884 DOI: 10.1038/Ncomms10739 |
0.705 |
|
| 2015 |
Perna F, Vu LP, Themeli M, Kriks S, Hoya-Arias R, Khanin R, Hricik T, Mansilla-Soto J, Papapetrou EP, Levine RL, Studer L, Sadelain M, Nimer SD. The polycomb group protein L3MBTL1 represses a SMAD5-mediated hematopoietic transcriptional program in human pluripotent stem cells. Stem Cell Reports. 4: 658-69. PMID 25754204 DOI: 10.1016/J.Stemcr.2015.02.003 |
0.597 |
|
| 2015 |
Park SM, Gönen M, Vu L, Minuesa G, Tivnan P, Barlowe TS, Taggart J, Lu Y, Deering RP, Hacohen N, Figueroa ME, Paietta E, Fernandez HF, Tallman MS, Melnick A, et al. Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. The Journal of Clinical Investigation. 125: 1286-98. PMID 25664853 DOI: 10.1172/Jci78440 |
0.738 |
|
| 2013 |
Vu LP, Perna F, Wang L, Voza F, Figueroa ME, Tempst P, Erdjument-Bromage H, Gao R, Chen S, Paietta E, Deblasio T, Melnick A, Liu Y, Zhao X, Nimer SD. PRMT4 blocks myeloid differentiation by assembling a methyl-RUNX1-dependent repressor complex. Cell Reports. 5: 1625-38. PMID 24332853 DOI: 10.1016/J.Celrep.2013.11.025 |
0.441 |
|
| 2011 |
Wang L, Gural A, Sun XJ, Zhao X, Perna F, Huang G, Hatlen MA, Vu L, Liu F, Xu H, Asai T, Xu H, Deblasio T, Menendez S, Voza F, et al. The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science (New York, N.Y.). 333: 765-9. PMID 21764752 DOI: 10.1126/Science.1201662 |
0.37 |
|
| 2009 |
Wang L, Huang G, Zhao X, Hatlen MA, Vu L, Liu F, Nimer SD. Post-translational modifications of Runx1 regulate its activity in the cell. Blood Cells, Molecules & Diseases. 43: 30-4. PMID 19386523 DOI: 10.1016/j.bcmd.2009.03.005 |
0.358 |
|
| Show low-probability matches. |